Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.

Ryder RE.

Diabet Med. 2013 Oct;30(10):1148-55. doi: 10.1111/dme.12301. Review. Erratum in: Diabet Med. 2013 Dec;30(12):1512.

PMID:
24073725
2.
3.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC.

Gastroenterology. 2011 Jul;141(1):150-6. doi: 10.1053/j.gastro.2011.02.018. Epub 2011 Feb 18.

4.

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.

Aroda VR, Ratner R.

Diabetes Metab Res Rev. 2011 Sep;27(6):528-42. doi: 10.1002/dmrr.1202. Review.

PMID:
21484979
5.

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.

Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.

Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z.

6.

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.

Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X.

BMJ. 2014 Apr 15;348:g2366. doi: 10.1136/bmj.g2366. Review.

7.

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.

Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.

Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2125-32. doi: 10.1161/ATVBAHA.116.307930. Epub 2016 Aug 25.

8.

The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.

Seufert J, Gallwitz B.

Diabetes Obes Metab. 2014 Aug;16(8):673-88. doi: 10.1111/dom.12251. Epub 2014 Jan 16. Review.

PMID:
24373150
9.

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E.

Diabetes Res Clin Pract. 2014 Feb;103(2):269-75. doi: 10.1016/j.diabres.2014.01.010. Epub 2014 Jan 14. Review.

PMID:
24485345
10.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Morales J.

Postgrad Med. 2011 Nov;123(6):189-201. doi: 10.3810/pgm.2011.11.2508. Erratum in: Postgrad Med. 2012 Jan;124(1):177-8.

PMID:
22104467
11.

GLP-1 receptor agonists: effects on cardiovascular risk reduction.

Lorber D.

Cardiovasc Ther. 2013 Aug;31(4):238-49. doi: 10.1111/1755-5922.12000. Review.

PMID:
23865382
12.

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.

Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20.

PMID:
23433305
13.

Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.

Blonde L, Montanya E.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:20-32. doi: 10.1111/j.1463-1326.2012.01575.x. Review.

PMID:
22405266
14.

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Jellinger PS.

Postgrad Med. 2011 Jan;123(1):53-65. doi: 10.3810/pgm.2011.01.2245. Review.

PMID:
21293084
15.

Incretin-based therapies: facing the realities of benefits versus side effects.

Lebovitz HE.

Diabetes Technol Ther. 2013 Nov;15(11):909-13. doi: 10.1089/dia.2013.0274. Epub 2013 Oct 10. No abstract available.

16.

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.

Mannucci E, Monami M.

Adv Ther. 2017 Jan;34(1):1-40. doi: 10.1007/s12325-016-0432-4. Epub 2016 Nov 14. Review.

17.

GLP-1-based therapies: the dilemma of uncertainty.

Spranger J, Gundert-Remy U, Stammschulte T.

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019. No abstract available.

PMID:
21723985
18.

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S.

Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.

PMID:
24989141
19.

Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?

Peterson G.

Ann Med. 2012 Jun;44(4):338-49. doi: 10.3109/07853890.2011.653392. Review.

PMID:
22530845
20.

The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.

Secrest MH, Udell JA, Filion KB.

Trends Cardiovasc Med. 2017 Apr;27(3):194-202. doi: 10.1016/j.tcm.2017.01.009. Epub 2017 Jan 28. Review.

PMID:
28291655

Supplemental Content

Support Center